Lentnek A L, Williams R R
Department of Medicine, Helene Fuld Medical Center, Trenton, New Jersey 08638.
Rev Infect Dis. 1991 May-Jun;13 Suppl 7:S586-90. doi: 10.1093/clinids/13.supplement_7.s586.
Aztreonam was administered to 122 patients with presumptive or confirmed gram-negative bacillary meningitis in an open, multinational study. The antibiotic was administered at a dosage of 1-2 g to adults, 50 mg/kg to children greater than 2 years old, and 30 mg/kg to infants three or four times daily. Seventy-seven patients had microbiologically confirmed gram-negative meningitis due to an aztreonam-susceptible organism and received aztreonam for at least 48 hours. Haemophilus influenzae was the most frequently recovered pathogen (40 patients), followed by Enterobacteriaceae (16 patients), Neisseria meningitidis (15 patients), and Pseudomonas species (six patients). All but four patients were microbiologically cured. Microbiologic failure was associated with either a persistent intracerebral abscess (one patient) or a foreshortened course of therapy before microbiologic reevaluation and death (at 48 hours, 48 hours, and 72 hours after initiation of treatment, respectively). These data suggest that aztreonam is effective in the treatment of gram-negative bacillary meningitis caused by susceptible organisms.
在一项开放性、多国性研究中，对122例疑似或确诊为革兰氏阴性杆菌脑膜炎的患者使用了氨曲南。抗生素的给药剂量为：成人1 - 2克，2岁以上儿童50毫克/千克，婴儿30毫克/千克，每日三或四次。77例患者经微生物学确诊为革兰氏阴性脑膜炎，病原体对氨曲南敏感，且接受氨曲南治疗至少48小时。流感嗜血杆菌是最常分离出的病原体（40例患者），其次是肠杆菌科（16例患者）、脑膜炎奈瑟菌（15例患者）和假单胞菌属（6例患者）。除4例患者外，所有患者均经微生物学方法治愈。微生物学治疗失败与持续性脑脓肿（1例患者）或在微生物学重新评估和死亡之前疗程缩短有关（分别在治疗开始后48小时、48小时和72小时死亡）。这些数据表明，氨曲南对由敏感病原体引起的革兰氏阴性杆菌脑膜炎有效。
